Mereo Biopharma Group Plc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Julian Harrison from BTIG maintained a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Julian Harrison’s rating is based on the promising outlook for Mereo Biopharma Group Plc’s Phase 3 Orbit trial, which is advancing to its final analysis. Despite the interim analysis not meeting the predefined threshold for disclosure, the extended follow-up period and increased statistical significance criteria suggest a high probability of positive results. The potential market for setrusumab is substantial, addressing a significant unmet need in osteogenesis imperfecta with a large target patient population in the US and Europe.
Furthermore, Mereo Biopharma holds valuable rights, including double-digit royalties on US net sales and significant milestones from Ultragenyx. The safety profile of setrusumab has been deemed acceptable, reinforcing its potential as a safe and effective treatment. These factors contribute to the expectation that the net present value of Mereo’s rights to setrusumab could exceed $1 billion, making the current stock weakness an attractive entry point for investors.
In another report released today, Needham also maintained a Buy rating on the stock with a $5.00 price target.